Show all
Stephen A. Hurly
President & Chief Executive Officer

Stephen A. Hurly brings nearly two decades of leadership experience in the life sciences industry. Prior to his role as president and CEO of Eleven, he joined Viventia as chief executive officer in March 2014. Previously, Mr. Hurly was the chief executive officer of Burrill & Co.'s Merchant Banking Division, a finance business for life science companies, from 2011 to 2014. Prior to that, Mr. Hurly was the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm, from 2008 to 2011. Mr. Hurly has more than 15 years of experience in the investment banking business. Mr. Hurly currently serves on the board of directors of PHusis Therapeutics Inc., a targeted small molecule therapeutics company, since May 2011. He graduated from Swarthmore College with a B.A. degree in Engineering in 1990 and earned an M.B.A. from the University of Chicago in 1997.

    Gregory P. Adams, Ph.D.
    Chief Scientific Officer

    Gregory P. Adams, Ph.D., serves as our chief scientific officer, leading the advancement of the company's oncology pipeline of novel Targeted Protein Therapeutics. Previously, Dr. Adams was Director of Biological Research and Therapeutics at Fox Chase Cancer Center from 2013 to 2015, where he led a laboratory group focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Earlier at Fox Chase Cancer Center, Dr. Adams co-lead the Center's Developmental Therapeutics Program from 2009 to 2013. Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He is a member of the Integration Panel of the U.S. Department of Defense's Breast Cancer Research Program and recently completed a four-year term as a member of the U.S. National Cancer Institute's Cancer Immunopathology and Immunotherapy Study Section. He was a co-founder of a computational antibody design company, RAbD Biotech, and has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals Inc., Symphogen A/S, Avipep Pty. Ltd., AvidBiologics (now known as Formation Biologics, Inc.) and YM Biosciences Inc. (which was acquired by Gilead Sciences, Inc.). He graduated from the University of California, Santa Cruz with a Bachelor's Degree in Biology in 1983 and earned a Ph.D. in Immunology from the University of California at Davis in 1991.

      David Brooks
      SVP, Clinical Development
      David is Sr. Vice President of Clinical Development at Eleven Biotherapeutics and Medical Monitor for the VISTA Phase 3 study of Vicinium in Non-Muscle Invasive Bladder Cancer. Prior to this David spent 13 years in roles of increasing of increasing responsibility in clinical research and translational medicine at Deciphera, Astra Zeneca, Tesaro, Abraxis and Merck. This includes development of oncology experimental therapeutics from pre-IND through late phase development as well as biomarker and diagnostics development. He trained in Internal Medicine and Medical Genetics at Penn and CHOP respectively becoming an Instructor in the Division of Medical Genetics at Hospital of the University of Pennsylvania in 2000. After pursuing a BA in Molecular, Cellular and Developmental Biology at The University of Colorado in Boulder, David completed the MD/PhD program at Cornell and Sloan-Kettering. David is a passionate advocate for immuno and targeted therapies in precision cancer medicine.
        Glen MacDonald, PhD
        Chief Technology Officer

        Glen C. MacDonald, Ph.D., serves as our chief technology officer. Previously, Dr. MacDonald served our predecessor company in several research related capacities from 1997 to 2005. Prior to joining us, Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a Post-Doctoral Fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society Post-Doctoral Fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a Bachelor’s Degree in Genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993, respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.

          Richard F. Fitzgerald
          Chief Financial Officer
          Richard F. Fitzgerald
          Richard F. Fitzgerald joined Eleven Biotherapeutics as its Interim Chief Financial Officer in October 2017. From July 2017 through October 2017, he served as a consultant to private life science based companies. Previously he served as the Chief Financial Officer of PAVmed Inc. (Nasdaq:PAVM) from October 2015 through March 2017 during which time PAVmed completed its IPO and Nasdaq listing. From April 2009 to October 2015, Mr. Fitzgerald was the Chief Financial Officer of TechPrecision Inc. (OTCBB: TPCS), a global manufacturer of precision large-scale components for the medical device, defense and energy industries. From 2002 to 2008, he served in various senior financial roles culminating in the role of Vice President and Chief Financial Officer of Nucleonics Inc., a venture-backed biotechnology company and early pioneer within the field of RNAi therapeutics whose assets were sold to Alnylam Pharmaceuticals Inc. (Nasdaq:ALNY) in December 2008. During his tenure at Nucleonics, he served as co-Chair of the Biotechnology Industry Organization’s (BIO) National CFO and Tax VP Committee, supporting federal tax, finance and capital formation lobbying efforts, and was active in the Association of Biotechnology Financial Officers. From 1995 to 2002, Mr. Fitzgerald served in the corporate development office and, from 1998 to 2002, as Director of Corporate Development for Exelon Corporation (NYSE:EXC), an energy generator and distributor, where he managed business development efforts, mergers and acquisitions, including the $18 billion merger with Unicom and the rollup of utility contractors which led to the formation of InfraSource (NYSE: IFS). From 1985 to 1995, Mr. Fitzgerald served as a Senior Manager in the Audit and Transaction Services Group of Coopers & Lybrand LLP (now PricewaterhouseCoopers). He is a member of the American and Pennsylvania Institutes of Public Accounting and a founding member of the Bucknell University Business Advisory Board. Mr. Fitzgerald received his B.S. in Business Administration and Accounting from Bucknell University.